Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Teva
Boehringer Ingelheim
McKinsey
Colorcon

Generated: September 19, 2019

DrugPatentWatch Database Preview

Patent: 4,798,800

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,798,800
Title: Process for isolating human globular domain NC1 of basal membrane collagen from human tissue
Abstract:The present invention provides human characterized by a molecular weight of about 170,000 Dalton, a hexameric structure with monomeric subunits with a molecular weight of about 28,000 Dalton and a carbohydrate content of about 2%. The present invention provides a process for obtaining and purifying globular domain NC1 of basal membrane collagen, wherein human or animal tissue is subjected to a first limiting treatment with bacterial collagenase, the degradation products obtained are separated from non-collagen proteins by chromatography on a weakly basic anion exchanger, the collagen degradation products are then subjected to a second collagenase digestion at an elevated temperature and the globular domain NC1 is purified by molecular sieve fractionation. Furthermore, the present invention is concerned with the use of this for the determination in body fluids in the case of the use of their antibodies, as well as far the detection of antibodies directed thereagainst in body fluids.
Inventor(s): Timpl; Rupert (Gauting, DE), Brocks; Dietrich (Hunfelden, DE)
Assignee: Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften e.V. (Gottingen, DE)
Application Number:06/664,538
Patent Claims:see list of patent claims

Details for Patent 4,798,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04 ➤ Sign Up Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften e.V. (Gottingen, DE) 2006-01-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Harvard Business School
Queensland Health
Julphar
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.